Mon, May 12, 2025
Sun, May 11, 2025

Zepbound users lost nearly 50% more weight than those on Wegovy in first head-to-head study

  Copy link into your clipboard //travel-leisure.news-articles.net/content/2025/ .. those-on-wegovy-in-first-head-to-head-study.html
  Print publication without navigation Published in Travel and Leisure on by Fortune
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source
That's according to the study funded by Eli Lilly, which was published Sunday in the New England Journal of Medicine.
In a groundbreaking head-to-head study, Eli Lilly's Zepbound was found to be significantly more effective for weight loss than Novo Nordisk's Wegovy, with Zepbound users losing 50% more weight on average. The study, which involved over 1,800 participants with obesity or overweight and related health issues, showed that after 32 weeks, those on Zepbound lost an average of 18.4% of their body weight, compared to 12.4% for those on Wegovy. Both drugs are weekly injections and belong to a class of medications known as GLP-1 receptor agonists, but Zepbound also targets another hormone, GIP, which may contribute to its superior weight loss results. The findings, presented at the American Diabetes Association's annual meeting, could influence future treatment choices for obesity and related conditions.

Read the Full Fortune Article at:
[ https://fortune.com/article/zepbound-users-lost-50-more-weight-wegovy-first-head-to-head-study/ ]


Similar Travel and Leisure Publications